VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+10.73%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$188M
AUM Growth
+$30.7M
(+19%)
Cap. Flow
+$19.9M
Cap. Flow
% of AUM
10.59%
Top 10 Holdings %
Top 10 Hldgs %
6.1%
Holding
495
New
69
Increased
189
Reduced
162
Closed
73
Top Buys
| 1 |
Palantir
PLTR
|
$1.01M |
| 2 |
BlackRock TCP Capital
TCPC
|
$1M |
| 3 |
Host Hotels & Resorts
HST
|
$993K |
| 4 |
DFS
Discover Financial Services
DFS
|
$989K |
| 5 |
Public Storage
PSA
|
$931K |
Top Sells
| 1 |
Burlington
BURL
|
$962K |
| 2 |
Prologis
PLD
|
$773K |
| 3 |
Booking.com
BKNG
|
$734K |
| 4 |
Eaton
ETN
|
$720K |
| 5 |
TE Connectivity
TEL
|
$708K |
Sector Composition
| 1 | Healthcare | 21.52% |
| 2 | Financials | 20.16% |
| 3 | Technology | 16.46% |
| 4 | Industrials | 8.76% |
| 5 | Energy | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
BlackRock Floating Rate Income Trust
BGT
$316M
| $526K | 0.28% |
40,538
+8,730
| +27% | +$113K |
|
177
Sixth Street Specialty
TSLX
$2.31B
| $523K | 0.28% |
24,399
+5,856
| +32% | +$125K |
|
178
Sarepta Therapeutics
SRPT
$1.95B
| $522K | 0.28% |
4,031
+580
| +17% | +$75.1K |
|
179
Hercules Capital
HTGC
$3.48B
| $513K | 0.27% |
27,782
-735
| -3% | -$13.6K |
|
180
Ascendis Pharma
ASND
$12.4B
| $480K | 0.25% |
3,172
+456
| +17% | +$68.9K |
|
181
Agios Pharmaceuticals
AGIO
$2.12B
| $479K | 0.25% |
16,395
+2,359
| +17% | +$69K |
|
182
Moderna
MRNA
$9.81B
| $473K | 0.25% |
4,437
+638
| +17% | +$68K |
|
183
Blackstone Secured Lending
BXSL
$6.72B
| $465K | 0.25% |
14,938
+5,048
| +51% | +$157K |
|
184
Main Street Capital
MAIN
$5.93B
| $463K | 0.25% |
9,784
+1,730
| +21% | +$81.8K |
|
|
DCF
185
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
| $452K | 0.24% |
52,445
+9,772
| +23% | +$84.1K |
|
186
Kiniksa Pharmaceuticals
KNSA
$2.64B
| $441K | 0.23% |
22,347
+3,215
| +17% | +$63.4K |
|
187
Neurocrine Biosciences
NBIX
$14.3B
| $433K | 0.23% |
3,140
+452
| +17% | +$62.3K |
|
|
BPMC
188
DELISTED
Blueprint Medicines
BPMC
| $431K | 0.23% |
4,546
+654
| +17% | +$62K |
|
189
Apellis Pharmaceuticals
APLS
$3.59B
| $429K | 0.23% |
7,302
+1,051
| +17% | +$61.8K |
|
190
Axsome Therapeutics
AXSM
$6.21B
| $415K | 0.22% |
5,200
+748
| +17% | +$59.7K |
|
191
CRISPR Therapeutics
CRSP
$4.92B
| $413K | 0.22% |
6,054
+871
| +17% | +$59.4K |
|
192
Ligand Pharmaceuticals
LGND
$3.25B
| $411K | 0.22% |
5,628
+810
| +17% | +$59.2K |
|
|
ITCI
193
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $404K | 0.21% |
5,833
+839
| +17% | +$58.1K |
|
194
PTC Therapeutics
PTCT
$4.56B
| $402K | 0.21% |
13,805
+1,986
| +17% | +$57.8K |
|
195
Halozyme
HALO
$8.7B
| $393K | 0.21% |
9,659
+1,390
| +17% | +$56.5K |
|
196
Amgen
AMGN
$153B
| $393K | 0.21% |
1,381
+200
| +17% | +$56.9K |
|
197
Exelixis
EXEL
$10.1B
| $388K | 0.21% |
16,346
+2,352
| +17% | +$55.8K |
|
198
Immunocore
IMCR
$1.86B
| $388K | 0.21% |
5,962
+858
| +17% | +$55.8K |
|
199
Ultragenyx Pharmaceutical
RARE
$3.08B
| $387K | 0.21% |
8,299
+1,194
| +17% | +$55.7K |
|
200
Rhythm Pharmaceuticals
RYTM
$6.85B
| $385K | 0.2% |
8,874
+1,277
| +17% | +$55.3K |
|